Return to Vaccination News Home Page

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

http://query.nytimes.com/gst/abstract.html?res=F10C1FFD39540C718CDDAF0894DB404482

National Desk | June 2, 2003, Monday
New Tacks in Cancer Treatment Show Promise in 2 Clinical Trials

By ANDREW POLLACK (NYT) 1559 words
Late Edition - Final , Section A , Page 1 , Column 1

ABSTRACT - Two experimental drugs that fight cancer in novel ways succeed in clinical trials, ending lingering doubts about their effectiveness and promising new era in treatment of disease; new drugs are products of biotechnology that attack particular mechanism by which cancer cells grow; they promise to extend by months lives of those who contract it or to shrink tumors, while avoiding some of serious side effects of conventional chemotherapy; they open door to further research that may yield wave of even more effective drugs operating on similar lines; one drug, Avastin, developed by Genentech, allowed patients with advanced colorectal cancer to live nearly five months longer; other drug is Erbitux, also tested on advanced colorectal cancer patients; it was developed by ImClone Systems, company dogged by scandal; its first application for approval of drug was rejected in 2001 because Food and Drug Adm said company's clinical trials were poorly designed and sloppily conducted; results of more carefully conducted trial are almost identical to those of pervious study, potentially clearing way for approval of drug; photo (M) Two experimental drugs that fight cancer in novel ways have succeeded in clinical trials, ending lingering doubts about their effectiveness and promising a new era in the treatment of the disease, doctors said here today.

The two new drugs, products of biotechnology, each attack a particular mechanism by which cancer cells grow.



 

PURCHASING FROM NYTIMES.COM IS QUICK AND SECURE.
To read the complete article, simply click on one of the BUY NOW buttons below.

You can buy this single article or, for even greater value, you can purchase this article as part of a multi-pack. You'll then have the opportunity to buy additional articles now or in the future at significant savings!

 
Purchase Single Article -- $2.95  
Purchase as part of Article 4-Pack -- $7.95
($1.99/article - a 33% savings!)
Pack expires after 1 month
 
 
Purchase as part of Article 10-Pack -- $15.95
($1.60/ article - a 46% savings!)
Pack expires after 3 months
 
 
Purchase as part of Article 25-Pack -- $25.95
($1.05/ article - a 65% savings!)
Pack expires after 6 months
 
 

How multi-packs work: A multi-pack is an archive package that saves you money by allowing you to pre-purchase a set number of articles in bulk at a reduced price. You can then debit from your multi-pack and quickly access articles from the archive at your convenience over the lifetime of the multi-pack.

Once you purchase an article, you may view it as often as you like over the next 90 days. Archive articles do not include photos, charts or graphics

Click here to purchase article if you already own an archive article pack.


Copyright 2003 The New York Times Company | Privacy Information

 

 

Return to Vaccination News Home Page

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.